机器人辅助腹腔镜前列腺癌根治术与开放耻骨后前列腺癌根治术:随机对照研究24个月结局
这项随机对照3期研究在326例新诊断局限性前列腺癌男性中比较了机器人辅助腹腔镜前列腺癌根治术与开放耻骨后前列腺癌根治术,随访24个月。结果显示两种术式在排尿功能和性功能评分上无显著差异,生化复发比例虽在 superiority 检验中显示差异,但等效性未能确立,影像学进展比例无显著差异。
要点
- 术后6、12、24个月排尿功能与性功能评分两种术式无显著差异。
核心结论
- 机器人辅助腹腔镜前列腺癌根治术与开放耻骨后前列腺癌根治术在24个月时功能结局相似。
- 肿瘤学结局需谨慎解读,因两组术后管理未标准化且使用额外抗癌治疗。
- 机器人入路的获益主要与其微创特性相关。
研究设计与样本
- 随机对照3期研究,纳入326例新诊断临床局限性前列腺癌且选择手术的35至70岁男性。
- 1:1随机分配至机器人辅助腹腔镜前列腺癌根治术(163例)或开放耻骨后前列腺癌根治术(163例)。
- 主要结局为6、12、24个月排尿功能(EPIC排尿域)和性功能(EPIC性功能域及IIEF)以及肿瘤学结局(生化复发和影像学进展证据)。
- 所有分析基于符合方案集。
关键数值与推荐
- 排尿功能采用EPIC排尿域评分,性功能采用EPIC性功能域及IIEF评分。
- 生化复发等效性检验预设界值为10%,基于90%CI。
临床怎么用
- 与患者沟通时,机器人辅助腹腔镜前列腺癌根治术的获益主要体现为微创特性,而非功能结局优势。
- 术后功能结局预期在两种术式间相似,决策可更多考虑微创相关因素。
- 肿瘤学结局解读需谨慎,因术后管理未标准化且部分患者接受额外抗癌治疗。
局限性
- 开放标签设计,但数据分析人员对手术分组设盲。
- 两组术后管理未标准化且使用额外抗癌治疗,影响肿瘤学结局解读。
- 等效性检验未能确立生化复发比例的等效性。
- 符合方案集分析,18例退出(开放组12例,机器人组6例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous trials have found similar early outcomes after robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy. We report functional and oncological postoperative outcomes up to 24 months after surgery for these two surgical techniques. METHODS: In this randomised controlled phase 3 study, men who had newly diagnosed clinically localised prostate cancer and who had chosen surgery as their treatment approach, and were aged between 35 years and 70 years were eligible and recruited from the Royal Brisbane and Women's Hospital (Brisbane, QLD, Australia). Participants were randomly assigned (1:1) to have either robot-assisted laparoscopic prostatectomy or open radical retropubic prostatectomy. Randomisation was computer generated and occurred in blocks of ten. This was an open trial; however, study investigators involved in data analysis were masked to each patient's surgical treatment. Primary outcomes were urinary function (urinary domain of Expanded Prostate Cancer Index Composite [EPIC]) and sexual function (sexual domain of EPIC and International Index of Erectile Function Questionnaire [IIEF]) at 6 months, 12 months, and 24 months and oncological outcome (biochemical recurrence and imaging evidence of progression). The trial was powered to assess health-related and domain-specific quality-of-life outcomes over 24 months. All analyses were done on a per-protocol basis. The trial was registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12611000661976. FINDINGS: Between Aug 23, 2010, and Nov 25, 2014, 326 men were enrolled, of whom 163 were randomly assigned to robot-assisted laparoscopic prostatectomy and 163 to open radical retropubic prostatectomy. 18 withdrew (12 assigned to radical retropubic prostatectomy and six assigned to robot-assisted laparoscopic prostatectomy); thus, 151 in the radical retropubic prostatectomy group and 157 in the robot-assisted laparoscopic prostatectomy group proceeded to surgery. At the 24-month follow-up time point, 150 men remained in the robot-assisted laparoscopic prostatectomy group and 146 remained in the open radical retropubic prostatectomy group. Urinary function scores did not differ significantly between robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy at 6 months post-surgery (88·68 [95% CI 86·79-90·58] vs 88·45 [86·54-90·36]; p1<0·0001, p2<0·0001), 12 months post-surgery (90·76 [88·89-92·62] vs 91·53 [90·07-92·98]; p1<0·0001, p2<0·0001), or 24 months post-surgery (91·33 [89·64-93·03] vs 90·86 [89·01-92·70]; p1<0·0001, p2<0·0001). Sexual function scores were not significantly different between robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy at 6 months post-surgery (EPIC: 37·40 [33·60-41·19] vs 38·63 [34·76-42·49], p1=0·0001, p2<0·0001; IIEF: 29·75 [26·66-32·84] vs 29·78 [26·41-33·16], p1<0·0001, p2<0·0001), 12 months post-surgery (EPIC: 42·28 [38·05-46·51] vs 42·51 [38·29-46·72], p1<0·0001, p2<0·0001; IIEF: 33·10 [29·59-36·61] vs 33·50 [29·87-37·13], p1=0·0002, p2<0·0001), or 24 months post-surgery (EPIC: 45·70 [41·17-50·23] vs 46·90 [42·20-51·60], p1=0·0003, p2<0·0001; IIEF: 33·95 [30·11-37·78] vs 33·89 [29·82-37·96], p1=0·0003, p2=0·0004). Equivalence testing on the difference between the proportion of biochemical recurrences between the two groups (13 [9%] in the open radical retropubic prostatectomy group vs four [3%] in the robot-assisted laparoscopic prostatectomy group) showed that equality between the two techniques could not be established based on a 90% CI with a prespecified margin of 10%. However, a superiority test showed that the two proportions were significantly different (p=0·0199). Equivalence testing on the proportion of patients who had imaging evidence of progression revealed that the two groups were not significantly different (p=0·2956). INTERPRETATION: Robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy yielded similar functional outcomes at 24 months. We advise caution in interpreting the oncological outcomes of our study because of the absence of standardisation in postoperative management between the two trial groups and the use of additional cancer treatments. Clinicians and patients should view the benefits of a robotic approach as being largely related to its minimally invasive nature. FUNDING: Cancer Council Queensland.
引用
- Coughlin GD, Yaxley JW, Chambers SK, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncol. 2018. PMID: 30017351. doi:10.1016/S1470-2045(18)30357-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。